Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TT-4 monotherapy in advanced solid tumors
NCT04976660Phase 2Withdrawn
- Sponsor
- Tarus Therapeutics
- Start
- Dec 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of PORT-7 in colorectal cancer (CRC), gastric cancer (GC), hepatocellular carcinoma (HCC) and 1 more, sponsored by Tarus Therapeutics. Primary endpoints: Number of subjects with Dose Limiting Toxicities at 28 days, Maximum Tolerated Dose or Recommended Phase 2 Dose up to 1 year and 1 more. Planned start Dec 2022; status: withdrawn.
02
Drugs
PORT-7
03
Conditions
colorectal cancer (CRC)gastric cancer (GC)hepatocellular carcinoma (HCC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04976660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04976660.